1. < Home

TGF-β

CD2-targeted nanoparticles encapsulating IL-2 induce tolerogenic Tregs and TGF-beta-producing NK cells that stabilize Tregs for long-term therapeutic efficacy in immune-mediated disorders

Horwitz DA, Kim D, Kang C, Brion K, Bickerton S, La Cava A. CD2-targeted nanoparticles encapsulating IL-2 induce tolerogenic Tregs and TGF-β-producing NK cells that[...]

By afschroeder • August 14, 2025
IL-13Rα2/TGF-β bispecific CAR-T cells counter TGF-β-mediated immune suppression and potentiate anti-tumor responses in glioblastoma

Hou AJ, Shih RM, Uy BR, Shafer A, Chang ZNL, Comin-Anduix B, Guemes M, Galic Z, Phyu S, Okada H, Grausam KB, Breunig JJ, Brown[...]

By sjmartinez • July 11, 2024
Bintrafusp alfa with cCRT followed by bintrafusp alfa versus placebo with cCRT followed by durvalumab in patients with unresectable stage III NSCLC: A phase 2 randomized study

Vokes EE, Mornex F, Sezer A, Cheng Y, Fang J, Baz DV, Cil T, Adjei AA, Ahn MJ, Barlesi F, Felip E, Garon EB, Audhuy[...]

By sjmartinez • October 6, 2023